BR112022017398A2 - Hidrato cristalino de um composto inibidor de jak - Google Patents

Hidrato cristalino de um composto inibidor de jak

Info

Publication number
BR112022017398A2
BR112022017398A2 BR112022017398A BR112022017398A BR112022017398A2 BR 112022017398 A2 BR112022017398 A2 BR 112022017398A2 BR 112022017398 A BR112022017398 A BR 112022017398A BR 112022017398 A BR112022017398 A BR 112022017398A BR 112022017398 A2 BR112022017398 A2 BR 112022017398A2
Authority
BR
Brazil
Prior art keywords
crystalline hydrate
inhibitor compound
jak inhibitor
compound
present
Prior art date
Application number
BR112022017398A
Other languages
English (en)
Inventor
Timothy Fass Gene
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of BR112022017398A2 publication Critical patent/BR112022017398A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

HIDRATO CRISTALINO DE UM COMPOSTO INIBIDOR DE JAK. É fornecido na presente invenção um hidrato cristalino do composto de fórmula 1. Composições farmacêuticas compreendendo tal hidrato cristalino, métodos de uso de tal hidrato cristalino para tratar doenças respiratórias e processos úteis para preparar tal hidrato cristalino também são fornecidos na presente invenção.
BR112022017398A 2020-03-02 2021-03-01 Hidrato cristalino de um composto inibidor de jak BR112022017398A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062983931P 2020-03-02 2020-03-02
PCT/US2021/070207 WO2021178991A1 (en) 2020-03-02 2021-03-01 Crystalline hydrate of a jak inhibitor compound

Publications (1)

Publication Number Publication Date
BR112022017398A2 true BR112022017398A2 (pt) 2022-10-18

Family

ID=75143791

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022017398A BR112022017398A2 (pt) 2020-03-02 2021-03-01 Hidrato cristalino de um composto inibidor de jak

Country Status (16)

Country Link
US (2) US11702415B2 (pt)
EP (1) EP4114836A1 (pt)
JP (1) JP2023516640A (pt)
KR (1) KR20220149585A (pt)
CN (1) CN115190878A (pt)
AR (1) AR121483A1 (pt)
AU (1) AU2021232100A1 (pt)
BR (1) BR112022017398A2 (pt)
CA (1) CA3172338A1 (pt)
CL (1) CL2022002368A1 (pt)
CO (1) CO2022012476A2 (pt)
IL (1) IL295613A (pt)
MX (1) MX2022010795A (pt)
TW (1) TW202144343A (pt)
WO (1) WO2021178991A1 (pt)
ZA (1) ZA202209617B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10947229B2 (en) * 2018-09-04 2021-03-16 Theravance Biopharma R&D Ip, Llc Dimethyl amino azetidine amides as JAK inhibitors
TW202144343A (zh) * 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
WO2023230236A1 (en) 2022-05-26 2023-11-30 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
AU2004259012C1 (en) 2003-07-23 2012-08-02 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
EP2414340A1 (en) 2009-04-03 2012-02-08 Dainippon Sumitomo Pharma Co., Ltd. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
WO2011084486A1 (en) 2009-12-21 2011-07-14 Epitherix, Llc 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
JP6192839B2 (ja) 2013-12-05 2017-09-06 ファイザー・インク ピロロ［２，３−ｄ］ピリミジニル、ピロロ［２，３−ｂ］ピラジニル、およびピロロ［２，３−ｄ］ピリジニルアクリルアミド
AU2015260905A1 (en) 2014-05-14 2016-12-01 Pfizer Inc. Pyrazolopyridines and pyrazolopyrimidines
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
CA3001542C (en) 2015-11-03 2021-02-16 Theravance Biopharma R&D Ip, Llc Jak kinase inhibitor compounds for treatment of respiratory disease
WO2017077283A1 (en) 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
US10556901B2 (en) * 2015-11-03 2020-02-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as Janus kinase inhibitors
PT3592742T (pt) 2017-03-09 2021-07-30 Theravance Biopharma R&D Ip Llc Inibidores de jak contendo uma amida heterocíclica com 4 membros
US20180258546A1 (en) 2017-03-09 2018-09-13 Lam Research Corporation Electroplating apparatus and methods utilizing independent control of impinging electrolyte
SG11201909376TA (en) 2017-05-01 2019-11-28 Theravance Biopharma R&D Ip Llc Crystalline forms of a jak inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
BR112019022665A2 (pt) 2017-05-01 2020-05-19 Theravance Biopharma R&D Ip Llc métodos de tratamento usando um composto inibidor de jak
CN112638902A (zh) 2018-09-04 2021-04-09 施万生物制药研发Ip有限责任公司 用于制备jak抑制剂的方法及其中间体
US10947229B2 (en) 2018-09-04 2021-03-16 Theravance Biopharma R&D Ip, Llc Dimethyl amino azetidine amides as JAK inhibitors
ES2955717T3 (es) 2018-09-04 2023-12-05 Theravance Biopharma R&D Ip Llc Amidas heterocíclicas de 5 a 7 elementos como inhibidores de JAK
CA3113667A1 (en) 2018-10-29 2020-05-07 Theravance Biopharma R&D Ip, Llc 2-azabicyclo hexane compound as jak inhibitor
BR112021016751B8 (pt) 2019-02-25 2023-11-21 Henan Medinno Pharmaceutical Tech Co Ltd Compostos, composições farmacêuticas e usos dos compostos
EP3934651A1 (en) 2019-03-05 2022-01-12 Incyte Corporation Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
CN112279848A (zh) 2019-07-25 2021-01-29 四川海思科制药有限公司 一种泛JAKs抑制剂及其用途
TW202144343A (zh) * 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物

Also Published As

Publication number Publication date
AU2021232100A1 (en) 2022-10-20
IL295613A (en) 2022-10-01
ZA202209617B (en) 2023-04-26
MX2022010795A (es) 2022-11-30
AR121483A1 (es) 2022-06-08
CO2022012476A2 (es) 2022-09-20
CA3172338A1 (en) 2021-09-10
KR20220149585A (ko) 2022-11-08
WO2021178991A1 (en) 2021-09-10
CL2022002368A1 (es) 2023-04-21
US20210269437A1 (en) 2021-09-02
EP4114836A1 (en) 2023-01-11
TW202144343A (zh) 2021-12-01
JP2023516640A (ja) 2023-04-20
US11702415B2 (en) 2023-07-18
CN115190878A (zh) 2022-10-14
US20240025897A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
BR112022017398A2 (pt) Hidrato cristalino de um composto inibidor de jak
MD3601283T2 (ro) Compus inhibitor JAK pe bază de imidazo-piperidină fuzionată
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
MX2022005839A (es) Compuestos utiles como inhibidores de la proteina helios.
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
EA202091016A1 (ru) Пиримидиновое соединение в качестве ингибитора jak киназы
MD20140037A2 (ro) Derivaţi de (4-fenilimidazol-2-il)etilamină utili ca modulatori ai canalului de sodiu
UY33500A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
MX2021002521A (es) Dimetilaminoazetidinaminas como inhibidores de jak.
BR112018011788A2 (pt) formas sólidas de éster etílico de ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, seus sais e um método de preparação
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
PE20200341A1 (es) Composiciones y compuestos terapeuticos y metodos para utilizarlos
CL2020001244A1 (es) Inhibidores de inmunoproteasoma.
MX2022006333A (es) Compuesto triheterociclico como inhibidor de jak y uso del mismo.
SG11201901962QA (en) Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof
MX2021009659A (es) Hidroxipiridoxazepinas como activadores de nrf2.
CR20220538A (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
BRPI0509667B8 (pt) composto, processo para a preparação de um composto de fórmula (i), medicamento e uso de um composto
CU23801B7 (es) Análogos de pirazol
BR112022016124A2 (pt) Composto de di-hidronaftiridinona, e método de preparação para este e uso médico deste
BR112019000813A2 (pt) formas sólidas de inibidor de ttk
MX2021009188A (es) Uso de composición que contiene inhibidor de quinasa dependiente de ciclina 4/6 en combinación con anastrozol en la preparación de medicamentos para el tratamiento de enfermedades tumorales.